Early this morning we announced an initiative to deliver and enhance a minimally invasive circulating tumor DNA (ctDNA) test to cancer patients across Canada in response to COVID-19.
July 15, 2020
A consortium led by Vancouver-based Canexia Health (formerly Contextual Genomics) will enable access to critical testing and treatment options for Canadian cancer patients during the COVID-19 pandemic.
June 15, 2020
In the last decade many new targeted therapies have been approved by the FDA.
March 18, 2020
Healthcare systems and providers around the world are coming together and adapting quickly to deliver care to patients under extraordinary circumstances as the coronavirus pandemic evolves.
January 17, 2020
Contextual Genomics and Eastern Ontario Regional Laboratory Association, a nonprofit organization offering high quality, patient focused, hospital-based lab services in Eastern Ontario, announced that they have partnered to bring Contextual Genomics’ ctDNA cancer genomic testing to EORLA’s Champlain Local Health Integration Network of Eastern Ontario, Canada.
January 13, 2020
Contextual Genomics and Lab Genomics, a personalized medicine company providing state of the art molecular genetic testing in Southern California, announced that they have signed an agreement enabling Lab Genomics to offer Contextual Genomics’ quality assured Next Generation Sequencing based ctDNA cancer genomic testing to patients in Southern California and other parts of the United States.
January 10, 2020
Contextual Genomics announced that it has named Brady Davis to its executive team. Mr. Davis, a veteran of the life sciences, healthcare and software industries, joins as Senior Vice President, Business Development of the Company, responsible for global strategy and business development.
Every Canexia Health report comes with therapeutic recommendations based on specific gene mutations and patient profiles, with clinical trials reviewed and selected by certified clinical molecular geneticists.